D. Rosmarin

发表

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

T. Bieber, M. Worm, M. Kawashima, 2019, The British journal of dermatology.

Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study

J. Thyssen, L. Strowd, M. Casillas, 2022, Journal of cutaneous medicine and surgery.

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey

D. Shrom, R. Burge, K. Sikand, 2019, Dermatology and Therapy.

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial

A. Gottlieb, M. Lebwohl, P. Grimes, 2020, The Lancet.

Tropical Dermatology

S. Lockwood, D. Rosmarin, A. Saavedra, 2020, Hunter's Tropical Medicine and Emerging Infectious Diseases.

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.

C. Calonder, A. Deodhar, G. Schett, 2021, Pharmacology & therapeutics.

The potential of interleukin 12 inhibition in the treatment of psoriasis.

B. Strober, D. Rosmarin, 2005, Journal of drugs in dermatology : JDD.

Response to ustekinumab in three pediatric patients with alopecia areata

D. Rosmarin, M. Her, P. Zancanaro, 2018, Pediatric dermatology.

Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges

D. Rosmarin, S. Pannu, 2021, American Journal of Clinical Dermatology.

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

D. Zillikens, K. Kridin, K. Amber, 2022, Frontiers in Medicine.

Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata

D. Rosmarin, P. Zancanaro, M. Abudu, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

A. Gottlieb, E. Martı́n-Mola, A. Deodhar, 2018, The Lancet.

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021

N. Konnikov, D. Rosmarin, J. Sobell, 2022, JAAD international.

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies

T. Buhl, E. Serra‐Baldrich, P. Fernández-Peñas, 2021, Dermatology and Therapy.

A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis

D. Rosmarin, P. Zancanaro, N. Dumont, 2019, Journal of the American Academy of Dermatology.

A Review of Tofacitinib in the Treatment of Rheumatoid Arthritis and Psoriasis

A. Gottlieb, D. Rosmarin, Kristina A Fanucci, 2014 .

Concomitant atopic dermatitis and psoriasis – a retrospective review

K. Barry, D. Rosmarin, P. Zancanaro, 2019, The Journal of dermatological treatment.

A retrospective review of dupilumab and psoriasis biologic combination therapy

K. Barry, D. Rosmarin, P. Zancanaro, 2019, The Journal of dermatological treatment.

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial.

A. Gottlieb, A. Saraiya, S. Au, 2020, Journal of the American Academy of Dermatology.

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

A. Gottlieb, A. Saraiya, D. Rosmarin, 2019, The British journal of dermatology.

Apremilast in Combination With an Interleukin 17A Inhibitor in the Treatment of Recalcitrant Palmoplantar Psoriasis

A. Gottlieb, D. Rosmarin, M. Her, 2018, Journal of Psoriasis and Psoriatic Arthritis.

Leukocytoclastic vasculitis flare following the COVID‐19 vaccine

A. Radfar, D. Rosmarin, S. Cohen, 2021, International journal of dermatology.

Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.

Bichchau T. Nguyen, Mahmoud Goodarzi, S. Au, 2017, Dermatology online journal.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

A. Gottlieb, V. Huang, A. Saraiya, 2017, Journal of the American Academy of Dermatology.

Linear trichilemmomas on the ankle of a 28‐year‐old female

D. Rosmarin, Jessica L. Gonzalez, C. Mannion, 2017, Journal of cutaneous pathology.

Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5)

M. Casillas, D. Rosmarin, Stacy R. Smith, 2022, Journal of cutaneous medicine and surgery.

Klippel-Trenauney syndrome with axillary hyperhidrosis.

G. Klement, S. Au, D. Rosmarin, 2017, Dermatology online journal.

Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.

D. Rosmarin, M. Her, A. Kaye, 2018, JAMA dermatology.

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.

P. Grimes, A. Wolkerstorfer, K. Ezzedine, 2022, The New England journal of medicine.

Addition of Narrow-Band Ultraviolet Light B (UVB) Phototherapy to Ruxolitinib Cream in Patients With Vitiligo.

M. Lebwohl, A. Pandya, I. Hamzavi, 2022, The Journal of investigative dermatology.

Guselkumab

D. Rosmarin, B. Rothstein, D. Joshipura, 2020, Reactions Weekly.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32‐week open‐label extension study with optional narrow‐band ultraviolet B

D. Rosmarin, P. Zancanaro, D. Joshipura, 2018, Journal of the American Academy of Dermatology.

Background information and treatment recommendations for patients with HIV/AIDS

J. Markowitz, J. Gorman, J. Rabkin, 2000 .

Toxic epidermal necrolysis.

D. Rosmarin, F. Pereira, A. Mudgil, 2007, Journal of the American Academy of Dermatology.

Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.

A. Gottlieb, B. Elewski, M. Lebwohl, 2010, Journal of the American Academy of Dermatology.

Recalcitrant Seborrheic Dermatitis Successfully Treated With Apremilast

D. Rosmarin, S. Cohen, S. Gordon, 2020, Journal of cutaneous medicine and surgery.

JAK‐STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis

D. Rosmarin, S. Deverapalli, J. Kahn, 2018, International journal of dermatology.

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

D. Rosmarin, K. N. Cunningham, K. Cunningham, 2023, American Journal of Clinical Dermatology.

Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series.

B. King, R. Waldman, M. Rothe, 2020, Journal of the American Academy of Dermatology.

Eosinophilic annular erythema treated with dupilumab

D. Rosmarin, S. Gellis, B. Schmidt, 2018, Pediatric dermatology.

8 – Tropical Dermatology

D. Rosmarin, A. Saavedra, 2013 .

Importance of light in the treatment of vitiligo with JAK-inhibitors

A. Gottlieb, D. Rosmarin, A. Goldminz, 2018, The Journal of dermatological treatment.

Repigmentation of hair following adalimumab therapy.

R. Kalish, D. Rosmarin, S. Tintle, 2015, Dermatology online journal.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

U. Wagner, A. Gottlieb, A. Orbai, 2017, The Lancet.

Hailey–Hailey disease treated with dupilumab: a case series

S. Tyring, D. Rosmarin, P. Zancanaro, 2021, The British journal of dermatology.

The use of JAK inhibitors in the treatment of progressive systemic sclerosis

D. Rosmarin, S. Deverapalli, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

A. Gottlieb, D. Rosmarin, N. Dumont, 2019, Journal of drugs in dermatology : JDD.

Efficacy of in‐class interleukin‐23 inhibitor switching: risankizumab following guselkumab failure in moderate‐to‐severe psoriasis treatment

D. Rosmarin, S. Pannu, J. Kahn, 2020, The British journal of dermatology.

Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results.

J. Silverberg, T. Bieber, A. Costanzo, 2021, The Journal of allergy and clinical immunology.

Anti IL‐17 flared psoriasis in a patient on secukinumab

A. Gottlieb, D. Rosmarin, B. McQuade, 2017, Dermatologic therapy.

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial

D. Shrom, K. See, D. Rosmarin, 2021, Skin health and disease.

Patch‐Testing While on Systemic Immunosuppressants

A. Gottlieb, D. Rosmarin, P. Scheinman, 2009, Dermatitis : contact, atopic, occupational, drug.

Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.

D. Rosmarin, Rachel G. Casseres, J. Kahn, 2019, Journal of the American Academy of Dermatology.

The Association of Professors of Dermatology Program Directors Task Force and Residency Program Transparency Work Group Guidelines on Residency Program Transparency.

A. Friedman, A. Murina, Jennifer T. Huang, 2020, Journal of drugs in dermatology : JDD.

Improving Information Transparency Between Dermatology Residency Programs and Trainees: Report from the Association of Professors of Dermatology Work Group on Transparency

A. Friedman, A. Murina, Jennifer T. Huang, 2020, Journal of the American Academy of Dermatology.

Successful treatment of disseminated granuloma annulare with adalimumab.

A. Gottlieb, S. Schlauder, D. Rosmarin, 2009, Journal of Drugs in Dermatology.

Adalimumab for the treatment of actinic granuloma

D. Rosmarin, Ari M. Goldminz, Jacqueline E Greb, 2017, Dermatologic therapy.

Patch testing a patient with allergic contact hand dermatitis who is taking infliximab.

D. Rosmarin, P. Scheinman, Michelle L Bush, 2008, Journal of the American Academy of Dermatology.

JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases

D. Rosmarin, S. Deverapalli, J. Kahn, 2018, Seminars in cutaneous medicine and surgery.

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. Reply.

K. Ezzedine, D. Rosmarin, D. Kornacki, 2023, The New England journal of medicine.

Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.

Jun Lu, M. Rothe, D. Rosmarin, 2023, Journal of the American Academy of Dermatology.

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

J. Silverberg, T. Bieber, J. Thyssen, 2023, The British journal of dermatology.

Treatment of patients experiencing dupilumab facial redness with itraconazole and fluconazole: a single institutional retrospective medical record review.

D. Rosmarin, N. Dumont, S. Cohen, 2021, Journal of the American Academy of Dermatology.

A Retrospective Review of Dupilumab for Hand Dermatitis

D. Rosmarin, P. Zancanaro, N. Dumont, 2019, Dermatology.

A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor

D. Rosmarin, S. Gordon, M. J. Her, 2019, Journal of the American Academy of Dermatology.

Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa

S. Schneeweiss, J. Merola, R. Wyss, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions

A. Gottlieb, D. Rosmarin, P. Zancanaro, 2019, The Journal of dermatological treatment.

Repigmentation in a patient with vitiligo on crisaborole 2% ointment

I. Tam, D. Rosmarin, J. Kahn, 2021, JAAD case reports.

Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Week 52 pooled subgroup analysis from two randomized phase 3 studies

P. Grimes, A. Wolkerstorfer, K. Ezzedine, 2023, British Journal of Dermatology.

Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa.

S. Schneeweiss, J. Merola, Seoyoung C. Kim, 2020, JAMA dermatology.

Comparison of constitutional and dermatologic side effects between COVID-19 and non–COVID-19 vaccines: Review of a publicly available database of vaccine side effects

D. Rosmarin, S. Cohen, J. Kahn, 2021, Journal of the American Academy of Dermatology.

Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate‐to‐severe atopic dermatitis

D. Rosmarin, N. Dumont, S. Cohen, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review.

D. Rosmarin, N. Dumont, S. Cohen, 2021, Dermatitis : contact, atopic, occupational, drug.

Real-World Treatment Patterns in Patients with Vitiligo in the United States

D. Rosmarin, A. Soliman, Chao Li, 2023, Dermatology and Therapy.

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations

M. Picardo, J. Bae, A. Wolkerstorfer, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Anti IL‐17 flared psoriasis in a patient on secukinumab

A. Gottlieb, D. Rosmarin, B. McQuade, 2017, Dermatologic therapy.

Using simulation modeling to minimize patient-to-patient contact time while optimizing clinical operations during a pandemic

Jacqueline A. Griffin, D. Rosmarin, Nurul Suhaimi, 2021, Journal of American Academy of Dermatology.

Operationally balancing resident education and patient wait times in an outpatient academic setting.

Jacqueline A. Griffin, Vahab Vahdat, D. Rosmarin, 2021, Journal of the American Academy of Dermatology.

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.

Luna Sun, D. Rosmarin, E. Pierce, 2023, The British journal of dermatology.

Treatment of patients with atopic dermatitis with weekly dupilumab dosing: a single institutional retrospective medical record review and survey.

D. Rosmarin, N. Dumont, S. Cohen, 2021, Journal of American Academy of Dermatology.

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

I. Hamzavi, N. van Geel, D. Rosmarin, 2024, EClinicalMedicine.

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm

M. Picardo, J. Bae, Youwen Zhou, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream

D. Rosmarin, F. Kuo, E. Boarder, 2023, JID innovations : skin science from molecules to population health.